Method for detecting lamivudine drug-resistant HBV DNA and its kit

Abstract

This invention involves the method of measuring Lamivudine's medicine-resisting HBV DNA and reagent box. Correlated with two kinds of main sudden change genes (YMDD sudden change is for YVDD and YIDD) design peculiar sudden change measure primer and virus peculiar measure primer and the public related probe, or design peculiar sudden change measure probe and virus peculiar measuring probe to conduct the real-time measure to the same sample respectively in three PCR tubes through the same PCR procedure. According to the D value of the Ct value in reaction tube 1, V reaction tube with the Ct value of the C reaction tube (í¸Ctú¡i=Ctú¡iú¡Ctú¡cú¼í¸Ctú¡v=Ctú¡vú¡Ctú¡c) to judge the YVDD and YIDD medicine-resisting sudden change situation of HBV in clinical sample. Advantages: stable reagent box performance, high sensitivity and so on.

Description

technical field

[0001] The invention relates to a method for detecting HBV DNA and a kit thereof, in particular to the detection of the drug resistance of hepatitis B virus lamivudine by using fluorescent labeled probes and specific primers. Background technique

[0002] Hepatitis B virus (HBV) is prevalent all over the world. It is estimated that 2 billion people are infected worldwide, of which 350 million are chronically infected, and my country accounts for about half of them. About 1 million people die from HBV infection every year. This infection can eventually develop into liver cirrhosis and liver cancer, which is currently the ninth leading cause of death in human diseases announced by WHO.

[0003] The current treatments for HBV infection mainly include interferon and lamivudine. Interferon has a long course of treatment and a low overall response rate. Only 20% to 30% of hepatitis B virus e antigen (HBeAg) disappears in non-selected patients. The curative effect ...